CXCR2 inhibitors

US8283479B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Stephanie Hachtel · Frankfurt am Main, DE
• Juergen Dedio · Frankfurt, DE
• Holger Heitsch · Hofheim, DE
• Werngard Czechtizky · Frankfurt, DE
• Sven Grueneberg · Kelkheim, DE
• Stephen Shimshock · Fryeburg, US
• Raymond W. Kosley, Jr. · Bound Brook, US
• Carolina Lanter · Audubon, US
• Hui Li · Santa Clara, US
• Rosy Sher · Bound Brook, US
• Aleksandra Weichsel · Tucson, US

Key dates

• Filing date: Apr 4, 2011
• Grant date: Oct 9, 2012
• Expiry date: Apr 4, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formula I:in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.